LongBio Pharma (Suzhou) Co., Ltd.
Research LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) on Bullrun: market cap HKD 5.68B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1779.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 5.68B
- Financial periodFY2025
- RevenueCNY 0
- Net income-CNY 175.58M
- Free cash flow-CNY 125.43M
Valuation Snapshot
latest market cap is HKD 5.68B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 175.58M | -CNY 125.43M | n/a | -2.37 | CNY 95.93M | CNY 37.92M | CNY 140.52M |
| FY2024 | CNY 0 | -CNY 137.32M | -CNY 110.27M | n/a | -1.85 | CNY 68.61M | CNY 44.91M | -CNY 330.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | HKD 5.68B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About LongBio Pharma (Suzhou) Co., Ltd.
LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. The company's products includes LP-003, an anti-IgE antibody with novel sequencing; LP-005, bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LongBio Pharma (Suzhou) Co., Ltd.'s market cap?
LongBio Pharma (Suzhou) Co., Ltd.'s market capitalization is HKD 5.68B.
What does LongBio Pharma (Suzhou) Co., Ltd. do?
LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. The company's products includes LP-003, an anti-IgE antibody with novel sequencing; LP-005, bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for specific tissues,organs and indications.